The Europe OTC parasiticides market is likely to grow at a CAGR of 6.26% during the forecast period. The market generated a revenue of around USD 300 Million at the end of 2021 and is likely to produce revenue worth of nearly USD 600 Million by the end of 2031. The market growth can majorly be attributed to the growing adoption of pets among European households, and the growing affection of people towards these animals. Further, growing concern for various diseases in animals, which in turn, may affect humans, is also expected to contribute to the market growth in the coming years.
The Europe OTC parasiticides market is segmented by product, animal, end user, distribution channel, and by country. On the basis of animal, the market is further fragmented into dogs, cats and others. The dogs segment is anticipated to garner the highest revenue of around USD 300 million by the end of 2031. The segment garnered a revenue of nearly USD 200 million in 2021. This growth is on the account of increasing demand for dogs as a home pet. Further, the dogs segment is to grow at a CAGR of about 6% over the forecast period.
On the basis of country, Europe OTC parasiticides market is analyzed by the markets of Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Spain, and Rest of Europe (EU 27). The Rest of Europe (EU 27) collected the highest revenue of about USD 200 million in 2021. By the end of 2031, it is estimated to garner a revenue of nearly USD 300 million, by growing at the CAGR of about 6% over the forecast period. Factors such as an increased number of vet doctors and higher adoption of pet and increased expenditure on animal health is expected to boost the market growth.
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the Europe OTC parasiticides market that are included in the report are Inovet, Merck & Co., Inc., Chanelle Pharma, Ceva Sante Animale, Vetoquinol S.A., Boehringer Ingelheim International GmbH, PetlQ, LLC., Syndel, and Elanco Animal Health Incorporated.
The Europe OTC parasiticides market is segmented by product, animal, end user, distribution channel, and by country. On the basis of animal, the market is further fragmented into dogs, cats and others. The dogs segment is anticipated to garner the highest revenue of around USD 300 million by the end of 2031. The segment garnered a revenue of nearly USD 200 million in 2021. This growth is on the account of increasing demand for dogs as a home pet. Further, the dogs segment is to grow at a CAGR of about 6% over the forecast period.
On the basis of country, Europe OTC parasiticides market is analyzed by the markets of Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Spain, and Rest of Europe (EU 27). The Rest of Europe (EU 27) collected the highest revenue of about USD 200 million in 2021. By the end of 2031, it is estimated to garner a revenue of nearly USD 300 million, by growing at the CAGR of about 6% over the forecast period. Factors such as an increased number of vet doctors and higher adoption of pet and increased expenditure on animal health is expected to boost the market growth.
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the Europe OTC parasiticides market that are included in the report are Inovet, Merck & Co., Inc., Chanelle Pharma, Ceva Sante Animale, Vetoquinol S.A., Boehringer Ingelheim International GmbH, PetlQ, LLC., Syndel, and Elanco Animal Health Incorporated.
Table of Contents
1. Europe OTC Parasiticides Market Definition1.1. Market Definition
1.2. Segmentation
2. Assumptions and Other Market Estimation Caveats
3. Research Methodology
4. Analyst Review
5. Executive Summary
6. Recent Development w.r.t. Parasiticides Market
7. Summary of the report
8. European Market Overview
9. Market Dynamics
9.1. Growth Drivers
9.2. Challenges
9.3. Market Trends
9.4. Opportunities
10. Regulatory & Standard Landscape
11. Industry Risk Analysis
12. Value Chain Analysis
13. Strategies Followed by the Market Players
13.1. Product development
13.2. Mergers & Acquisitions
13.3. Joint venture
13.4. Product Launch
13.5. R&D Investment
14. Epidemiology Analysis
14.1. Prevalence of Zoonotic Disease
14.2. Prevalence of Ectoparasites, Endoparasiticides, and Endectocides
15. Patent Expiry Analysis of Key Drugs in Different Jurisdiction
15.1. Formulation Patent
15.2. Supplementing Protection Certificates (SPCs)
16. Sales Analytics of Key Drugs
16.1. Seresto
16.2. Frontline
16.3. Advantage
16.4. Others
17. Rx to OTC Switch Analysis
17.1. Present Scenario
17.2. Future outlook
18. Pipeline Analysis of Major Players
19. Market Opportunity Analysis
20. Types of Formulation Analysis
20.1. Topical
20.2. Oral
20.3. Injectable
21. Competitive Landscape
21.1. Competitive Positioning
21.2. Market Share Analysis, 2021
21.3. Company Profiles
21.3.1. Inovet
21.3.1.1. Detailed Overview
21.3.1.2. Mergers & Acquisitions
21.3.1.3. Assessment of Key Product Offerings
21.3.1.4. Analysis of Growth Strategies
21.3.1.5. Exhaustive Analysis on Key Financial Indicators
21.3.1.6. Recent Developments
21.3.2. Merck & Co., Inc.,
21.3.3. Chanelle Pharma
21.3.4. Ceva Sante Animale
21.3.5. Vetoquinol S.A.
21.3.6. Boehringer Ingelheim International GmbH
21.3.7. PetlQ, LLC.
21.3.8. Syndel
21.3.9. Elanco Animal Health Incorporated
22. Europe OTC Parasiticides Market (Companion Animals)
22.1. Market Overview
22.2. By Value (USD million)
22.3. By Product Type
22.3.1. Ectoparasiticides, 2021-2031F (USD Million)
22.3.1.1. Pour On, 2021-2031F (USD Million)
22.3.1.2. Spot On, 2021-2031F (USD Million)
22.3.1.3. Sprays, 2021-2031F (USD Million)
22.3.1.4. Others, 2021-2031F (USD Million)
22.3.2. Endoparasiticides, 2021-2031F (USD Million)
22.3.2.1. Injectable, 2021-2031F (USD Million)
22.3.2.2. Oral, 2021-2031F (USD Million)
22.3.2.2.1. Liquids, 2021-2031F (USD Million)
22.3.2.2.2. Tablets, 2021-2031F (USD Million)
22.3.2.2.3. Others, 2021-2031F (USD Million)
22.3.3. Endectocides, 2021-2031F (USD Million)
22.4. By Animal Type
22.4.1. Dogs, 2021-2031F (USD Million)
22.4.2. Cats, 2021-2031F (USD Million)
22.4.3. Others, 2021-2031F (USD Million)
22.5. By End User
22.5.1. Personal user, 2021-2031F (USD Million)
22.5.2. Commercial user, 2021-2031F (USD Million)
22.6. By Distribution Channel
22.6.1. Online, 2021-2031F (USD Million)
22.6.2. Offline, 2021-2031F (USD Million)
23. By Country
23.1. Belgium
23.1.1. By Product Type
23.1.1.1. Ectoparasiticides, 2021-2031F (USD Million)
23.1.1.1.1. Pour On, 2021-2031F (USD Million)
23.1.1.1.2. Spot On, 2021-2031F (USD Million)
23.1.1.1.3. Sprays, 2021-2031F (USD Million)
23.1.1.1.4. Others, 2021-2031F (USD Million)
23.1.1.2. Endoparasiticides, 2021-2031F (USD Million)
23.1.1.2.1. Injectable, 2021-2031F (USD Million)
23.1.1.2.2. Oral, 2021-2031F (USD Million)
23.1.1.2.2.1. Liquids, 2021-2031F (USD Million)
23.1.1.2.2.2. Tablets, 2021-2031F (USD Million)
23.1.1.2.2.3. Others, 2021-2031F (USD Million)
23.1.1.3. Endectocides, 2021-2031F (USD Million)
23.1.2. By Animal Type
23.1.2.1. Dogs, 2021-2031F (USD Million)
23.1.2.2. Cats, 2021-2031F (USD Million)
23.1.2.3. Others, 2021-2031F (USD Million)
23.1.3. By End User
23.1.3.1. Personal user, 2021-2031F (USD Million)
23.1.3.2. Commercial user, 2021-2031F (USD Million)
23.1.4. By Distribution Channel
23.1.4.1. Online, 2021-2031F (USD Million)
23.1.4.2. Offline, 2021-2031F (USD Million)
23.2. Czech Republic
23.2.1. By value (USD million)
23.2.2. By Product Type
23.2.3. By Animal Type
23.2.4. By End User
23.2.5. By Distribution Channel
23.3. France
23.3.1. By value (USD million)
23.3.2. By Product Type
23.3.3. By Animal Type
23.3.4. By End User
23.3.5. By Distribution Channel
23.4. Germany
23.4.1. By value (USD million)
23.4.2. By Product Type
23.4.3. By Animal Type
23.4.4. By End User
23.4.5. By Distribution Channel
23.5. Greece
23.5.1. By value (USD million)
23.5.2. By Product Type
23.5.3. By Animal Type
23.5.4. By End User
23.5.5. By Distribution Channel
23.6. Italy
23.6.1. By value (USD million)
23.6.2. By Product Type
23.6.3. By Animal Type
23.6.4. By End User
23.6.5. By Distribution Channel
23.7. Netherlands
23.7.1. By value (USD million)
23.7.2. By Product Type
23.7.3. By Animal Type
23.7.4. By End User
23.7.5. By Distribution Channel
23.8. Poland
23.8.1. By value (USD million)
23.8.2. By Product Type
23.8.3. By Animal Type
23.8.4. By End User
23.8.5. By Distribution Channel
23.9. Portugal
23.9.1. By value (USD million)
23.9.2. By Product Type
23.9.3. By Animal Type
23.9.4. By End User
23.9.5. By Distribution Channel
23.10. Spain
23.10.1. By value (USD million)
23.10.2. By Product Type
23.10.3. By Animal Type
23.10.4. By End User
23.10.5. By Distribution Channel
23.11. Rest of Europe (EU-27)
23.11.1. By value (USD million)
23.11.2. By Product Type
23.11.3. By Animal Type
23.11.4. By End User
23.11.5. By Distribution Channel
Companies Mentioned
- Inovet
- Merck & Co. Inc.
- Chanelle Pharma
- Ceva Sante Animale
- Vetoquinol S.A.
- Boehringer Ingelheim International GmbH
- PetlQ LLC.
- Syndel
- Elanco Animal Health Incorporated.
